Display Settings:

Format

Send to:

Choose Destination

    Lancet. 2006 Apr 22;367(9519):1343-51.

    Amblyopia.

    Holmes JM, Clarke MP.

    Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. holmes.jonathan@mayo.edu

    Results from recent randomised clinical trials in amblyopia should change our approach to screening for and treatment of amblyopia. Based on the current evidence, if one screening session is used, screening at school entry could be the most reasonable time. Clinicians should preferably use age-appropriate LogMAR acuity tests, and treatment should only be considered for children who are clearly not in the typical range for their age. Any substantial refractive error should be corrected before further treatment is considered and the child should be followed in spectacles until no further improvement is recorded, which can take up to 6 months. Parents and carers should then be offered an informed choice between patching and atropine drops. Successful patching regimens can last as little as 1 h or 2 h a day, and successful atropine regimens as little as one drop twice a week. Intense and extended regimens might not be needed in initial therapy.

    PMID: 16631913 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Hyoscyamine (Anaspaz®, Cystospaz®, Cystospaz-M®, ...)

      Hyoscyamine is used to control symptoms associated with disorders of the gastrointestinal (GI) tract. It works by decreasing the motion of the stomach and intestines and the secretion of stomach fluids, including acid. H...